Risultati di uno studio randomizzato che valuta la sicurezza e l'efficacia del cenobamate nei pazienti con epilessia focale non controllata pubblicato su The Lancet Neurology ZUG, Svizzera, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Arvelle Therapeutics GmbH, una società biofarmaceutica emergente focalizzata su trattamenti innovativi per pazienti con disturbi del sistema nervoso...

Arvelle to Present at Jefferies 2019 London Healthcare Conference Arvelle to Present at Jefferies 2019 London Healthcare Conference Zug, Switzerland, November 15, 2019 - Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on...

Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology ZUG, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, today...

Arvelle Therapeutics Strengthens Management Team with Key New Hires Arvelle Therapeutics Strengthens Management Team with Key New Hires Appoints Petra Molan as Senior Vice President Commercial and                                                   Enrico Dolfini as...